dextroamphetamine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Negus, SS | 1 |
| Banks, ML | 1 |
| Berton, AM | 1 |
| Prencipe, N | 1 |
| Giordano, R | 1 |
| Ghigo, E | 1 |
| Grottoli, S | 1 |
2 other studies available for dextroamphetamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Confronting the challenge of failed translation in medications development for substance use disorders.
Topics: Analgesics, Opioid; COVID-19; Dextroamphetamine; Dopamine Agonists; Dopamine Antagonists; Drug Devel | 2021 |
Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Amobarbital; Anti-Inflammatory Agents; COVID-19; COV | 2021 |